The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York October 29, 2024 Pharmacy Compounding Advisory Committee Meeting Industry Update: Interim 503A and 503B Bulks Lists New Revisions FDA Approved Peptides List (2026): Complete Safety Guide Pharm D Solutions, LLC Issues Voluntary Nationwide Recall of All Sterile Compounded Drugs Due to a Potential Lack of Sterility Assurance FDA